Should patients with atrial fibrillation and stable coronary artery disease receive an oral anticoagulant, an antiplatelet or both?

EBM Verdict on: Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl
J Med 2019;381:1103-–1113. doi: 10.1056/ NEJMoa1904143.
In patients with atrial fibrillation and stable coronary artery disease, monotherapy with rivaroxaban is non-inferior to combination therapy with rivaroxaban and an antiplatelet in terms of preventing death and cardiovascular events. Rivaroxaban monotherapy is associated with less major bleeding.

Leave a Reply

Your email address will not be published. Required fields are marked *